Alterity Therapeutics (ASX:ATH)
Company Profile
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Alterity Therapeutics.
RELATED STOCKHEAD STORIES
Dr Boreham’s Crucible: This MSA-tackling biotech strives to be ‘different’
Health Check: Ansell gloves up for Trump tariff threat
Health Check: Percheron ‘closes the book’ on failed childhood rare disease program
Health Check: Good golly Miss Molly! Emyria says Ecstasy works for PTSD, months after treatment
ASX Lunch Wrap: ASX rises despite Fed’s wait-and-see; Alibaba’s AI shakes Nvidia
Health Check: Alterity angles for fast-track FDA approval after positive trial results tackling Parkinson’s-like disorder
Health Check: Chinese consumer market is a thing of beauty, says EZZ Life Sciences
Health Check: Mayne Pharma and Acrux are on a drug expansion drive, generically speaking
Health Check: Prestigious publication supports Alterity’s ‘iron overload in brain’ thesis
ASX Small Caps Lunch Wrap: ASX up 0.8pc, job vacancies fall and Star punts on $200m bailout
‘Holy Grail’ – Alterity Therapeutics aims to slow progression of Parkinson’s disease
Closing Bell: Intense relief as ASX rallies on easing inflation
Top 10 at 11: This morning’s news is about all the hot quarterly action you can handle
